coronaviru
first
discov
speci
envelop
positivesens
rna
viru
classifi
order
nidoviral
famili
coronavirida
subfamili
coronavirina
see
figur
virus
infect
cell
certain
vertebr
host
character
clublik
spike
protrud
surfac
subfamili
coronavirina
split
four
main
genera
coronaviru
basi
serolog
genom
properti
alphacoronaviru
betacoronaviru
gammacoronaviru
deltacoronaviru
betacoronaviru
split
four
lineag
b
c
see
figur
recent
identifi
sever
acut
respiratori
syndrom
coronaviru
classifi
subgenu
sarbecoviru
genu
lineag
b
betacoronaviru
due
widespread
avail
larg
genet
divers
frequent
recombin
coronaviru
speci
conjunct
increas
time
human
spend
presenc
anim
coronavirus
occasion
abl
mutat
infect
human
host
list
coronavirus
discov
thu
far
six
speci
known
infect
human
host
also
known
hcov
caus
mild
seriou
respiratori
symptom
depend
lineag
coronaviru
well
immunocompromis
natur
patient
new
coronaviru
initi
name
novel
coronaviru
first
discov
cluster
patient
report
symptom
pneumonia
unknown
caus
local
chines
health
facil
wuhan
hubei
provinc
earli
decemb
howev
origin
sourc
novel
coronaviru
unclear
februari
given
name
sever
acut
respiratori
syndrom
coronaviru
announc
coronaviru
studi
group
csg
intern
committe
taxonomi
virus
refer
world
health
organ
name
guidelin
timelin
develop
shown
see
figur
past
year
zoonot
pathogen
coronavirus
led
global
region
outbreak
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
although
ident
much
could
still
learn
previou
outbreak
knowledg
experi
incorpor
current
effort
understand
well
strategi
prevent
treatment
sarscov
first
emerg
outbreak
pneumonia
guangdong
provinc
peopl
republ
china
novemb
although
may
first
coronaviru
infect
human
certainli
first
outbreak
modern
histori
real
signific
empir
antimicrobi
treatment
acut
communityacquir
typic
atyp
pneumonia
prove
ineffect
handl
disord
upon
investig
pathogen
caus
pneumonia
found
pathogen
never
identifi
previous
thu
give
disord
name
sever
acut
respiratori
distress
syndrom
sar
sar
caus
new
type
coronaviru
sarscov
incub
period
day
patient
began
develop
flulik
symptom
pneumonia
mention
end
epidem
june
sar
led
case
worldwid
mortal
rate
approxim
effort
taken
identifi
sourc
sarscov
prevent
futur
sar
outbreak
accord
studi
anim
sampl
taken
liveanim
market
guangdong
found
mask
palm
civet
two
speci
alreadi
infect
sarscov
sarscov
zoonot
led
tent
largescal
cull
mask
palm
civet
howev
studi
later
reveal
widespread
infect
found
wild
farm
civet
clinic
symptom
sar
shown
overt
civet
sold
market
suggest
civet
highli
unlik
primarynatur
reservoir
host
studi
li
et
al
drew
attent
bat
abil
host
sever
zoonot
virus
whilst
rare
display
clinic
symptom
addit
increas
consumpt
bat
batbas
product
southern
china
arous
suspicion
bat
might
primari
host
sarscov
upon
collect
test
serum
sampl
cdna
bat
nine
speci
six
genera
three
famili
li
et
al
observ
sarscov
test
posit
differ
speci
horsesho
bat
rhinolophu
genu
observ
conclud
horsesho
bat
primari
host
sarscov
subsequ
pass
intermedi
host
civet
eventu
human
merscov
first
discov
summer
jeddah
saudi
arabia
unknown
coronaviru
time
isol
sputum
patient
experienc
acut
pneumonia
renal
failur
case
could
link
back
april
healthcar
worker
hospit
zarqa
start
develop
symptom
pneumonia
find
alarm
due
clinic
resembl
sar
minor
patient
experienc
mild
diseas
whilst
major
patient
experienc
sever
acut
respiratori
condit
merscov
outbreak
reach
sever
countri
sever
outbreak
found
saudi
arabia
south
korea
lead
case
worldwid
mortal
rate
approxim
mostli
consist
children
elderli
peopl
compromis
immun
system
similar
sarscov
merscov
zoonot
believ
transmit
human
via
contact
dromedari
camel
dromedari
camel
also
believ
intermedi
host
clear
answer
origin
merscov
except
accord
differ
viru
genom
analysi
may
origin
bat
transmit
viru
dromedari
camel
distant
past
fortun
humantohuman
transmiss
merscov
fairli
uncommon
close
contact
need
made
order
viru
pass
anoth
human
host
limit
spread
viru
patient
confirm
case
januari
januari
wuhan
jinyintan
hospit
studi
found
form
previou
exposur
huanan
seafood
wholesal
market
live
anim
sale
fulllength
genom
sequenc
releas
earli
stage
outbreak
studi
reveal
ident
bat
coronaviru
wholegenom
level
belong
speci
sarscov
transmiss
electron
microscop
tem
imag
shown
figur
accord
test
carri
phan
et
al
nucleotid
sequenc
compar
type
alreadi
known
coronavirus
use
pairwis
sequenc
analysi
test
result
demonstr
nucleotid
similar
batsar
coronaviru
see
figur
similar
signific
margin
compar
rest
known
zoonot
coronavirus
less
nucleotid
similar
although
definit
suggest
huanan
seafood
wholesal
market
potenti
close
link
viru
sourc
sourc
suggest
bat
primari
reservoir
zoonot
well
pathogen
make
one
coronaviru
speci
potenti
transmit
anim
human
host
properti
well
long
period
time
human
anim
spend
close
proxim
one
anoth
allow
viru
spread
differ
host
rapid
rate
result
global
region
outbreak
although
current
evid
respiratori
diseas
infect
anim
human
host
develop
respiratori
symptom
phenomena
also
observ
previou
sarscov
merscov
outbreak
still
vaccin
avail
sarscov
merscov
classifi
subfamili
coronavirina
therefor
zoonot
display
abil
transfer
intermedi
human
host
mention
previous
sarscov
outbreak
occur
civet
play
role
intermedi
host
pass
viru
human
host
whilst
dromedari
camel
play
role
intermedi
host
pass
viru
human
merscov
outbreak
sarscov
growth
factor
wherea
merscov
growth
factor
less
intermedi
host
pass
viru
human
still
remain
unclear
due
presenc
sever
anim
speci
huanan
seafood
wholesal
market
full
sequenc
releas
research
phylogenet
analysi
reveal
gene
sequenc
ident
bat
sarslik
coronaviru
access
ident
sarscov
suggest
also
belong
betacoronaviru
lineag
b
closer
homolog
sarscov
structur
analysi
spike
protein
new
viru
show
protein
bind
weakli
angiotensinconvert
enzym
receptor
human
cell
wherea
human
sarscov
exhibit
strong
affin
ace
receptor
despit
bind
strength
still
much
higher
threshold
requir
viru
infect
although
import
show
potenti
humantohuman
transmiss
also
show
bind
receptor
may
factor
affect
viru
transmiss
addit
increas
evid
point
humantohuman
transmiss
hospit
famili
gather
studi
conduct
chen
et
al
medic
report
patient
januari
examin
age
patient
rang
year
old
mean
age
approxim
patient
femal
male
sampl
patient
half
suffer
underli
cardiovascular
cerebrovascular
diseas
would
appear
older
individu
andor
individu
compromis
immun
system
greater
risk
infect
addit
although
preliminari
would
seem
though
link
sex
patient
lower
number
femal
patient
observ
particular
group
patient
could
potenti
attribut
natur
immun
system
protect
x
chromosom
sex
hormon
see
figur
known
play
key
role
innat
adapt
immun
thu
less
suscept
variou
infect
said
observ
studi
need
confirm
relationship
patient
also
display
variou
clinic
symptom
fever
cough
short
breath
muscl
ach
confus
headach
sore
throat
rhinorrhea
chest
pain
diarrhea
nausea
vomit
see
figur
approxim
patient
observ
one
symptom
wherea
experienc
fever
cough
short
breath
simultan
laboratori
test
display
overal
fall
valu
lymphocyt
suggest
might
mainli
target
lymphocyt
specif
lymphocyt
spread
respiratori
mucosa
trigger
immun
respons
neg
chang
immun
system
would
potenti
caus
acut
respiratori
distress
syndrom
ard
septic
shock
patient
lead
eventu
organ
failur
februari
total
death
coronaviru
diseas
report
confirm
case
differ
countri
accord
live
updat
number
death
result
shown
rise
overal
daili
growth
factor
suggest
exponenti
growth
number
death
januari
februari
see
figur
accord
studi
medic
report
carri
zhao
et
al
total
number
unreport
case
januari
januari
estim
growth
factor
outbreak
take
place
middl
flu
season
symptom
earli
stage
could
ignor
gone
unreport
due
similar
symptom
common
influenza
allow
infect
progress
later
sever
stage
mortal
rate
estim
thu
far
may
chang
due
lack
inform
obscur
full
pictur
outbreak
first
day
announc
pandem
instead
public
health
emerg
intern
concern
studi
zhong
et
al
show
acut
respiratori
distress
ard
caus
diagnos
amongst
whole
spectrum
age
wherea
patient
age
median
age
male
common
clinic
symptom
fever
cough
groundglass
opac
bilater
patchi
shadow
typic
found
chest
computer
tomographi
ct
scan
figur
show
groundglass
opac
infect
lung
male
femal
patient
similar
age
rang
median
incub
period
day
incub
period
rang
day
rel
lower
fatal
rate
sarscov
merscov
found
mortal
rate
base
larger
sampl
size
studi
lower
report
previous
mention
section
detail
genom
structur
analysi
show
similar
sarscov
close
deriv
zoonot
bat
coronavirus
howev
accord
structur
analysi
spike
protein
protein
show
form
weak
bond
receptor
human
cell
suggest
viru
may
transmit
readili
human
host
reduc
contagi
reproduct
number
howev
patient
laboratoryconfirm
studi
zhong
et
al
direct
contact
wildlif
thu
suggest
high
potenti
humantohuman
transmiss
rout
transmiss
might
acceler
spread
apart
respiratori
droplet
direct
contact
serv
convent
rout
transmiss
sarscov
merscov
highli
pathogen
influenza
fomit
transmiss
found
potenti
reason
rapid
transmiss
observ
januari
show
infect
sharpli
increas
span
day
reach
total
confirm
case
medic
worker
associ
previou
patient
host
anoth
studi
carri
chan
et
al
six
famili
member
travel
wuhan
shenzhen
guangdong
provinc
china
monitor
five
test
posit
despit
come
contact
market
anim
wuhan
outbreak
start
addit
famili
member
also
report
contract
diseas
sever
day
come
contact
four
famili
member
observ
reinforc
fact
transmit
human
host
anoth
human
host
also
suggest
may
abl
undergo
mutat
adapt
infect
human
host
easili
creat
urgenc
find
method
contain
mutat
method
predict
whether
mutat
lead
infect
futur
avail
yet
conduct
valid
accord
current
basic
reproduct
number
estim
within
exceed
sarscov
mean
human
host
averag
spread
viru
host
thu
far
humantohuman
infect
classifi
second
gener
transmiss
yet
known
case
third
gener
transmiss
human
infect
anoth
human
previous
infect
anoth
human
occur
could
spell
increas
reproduct
number
possibl
viru
transmit
apart
china
humantohuman
transmiss
report
countri
germani
japan
thailand
unit
state
paper
publish
new
england
journal
medicin
nejm
report
first
four
case
germani
associ
businesswoman
shanghai
travel
compani
munich
januari
four
peopl
met
soon
start
experienc
clinic
symptom
later
report
businesswoman
experienc
symptom
time
lead
expert
believ
asymptomat
patient
abl
transmit
well
although
later
found
businesswoman
suppress
symptom
paracetamol
yet
enough
evid
rule
potenti
asymptomat
transmiss
discuss
section
number
peopl
one
infect
person
spread
defin
reproduct
number
import
understand
averag
number
peopl
one
infect
host
infect
therefor
chang
accord
differ
scenario
viru
spread
long
infect
host
spread
viru
recov
make
valu
differ
everi
locat
pattern
still
emerg
countri
accord
studi
conduct
imai
et
al
basi
frequenc
intern
travel
wuhan
januari
averag
valu
wuhan
found
uncertainti
rang
show
averag
infect
person
wuhan
could
potenti
spread
viru
roughli
patient
anoth
studi
carri
zhao
et
al
report
estim
rang
within
basi
confirm
case
report
wuhan
januari
januari
work
et
al
wuhan
estim
within
rang
initi
period
epidem
decemb
drop
januari
show
current
effort
quarantin
travel
restrict
contact
trace
intervent
effect
control
outbreak
said
number
infect
individu
china
expect
reach
peak
earli
march
current
moment
sourc
display
valu
henc
exponenti
growth
number
case
expect
research
explor
wide
rang
resourc
examin
transmiss
dynam
better
prevent
control
current
outbreak
origin
diffus
epicentr
investig
via
phylogeni
maximumlikelihood
map
analys
basi
timescal
phylogenet
analysi
viru
genom
sequenc
potenti
larg
first
gener
humantohuman
viru
transmiss
estim
occur
novemb
similarli
phylogeograph
analysi
two
geograph
locat
earliest
confirm
case
report
primarili
wuhan
china
bangkok
thailand
reveal
viral
transmiss
epidemiolog
link
citi
potenti
origin
wuhan
posterior
probabl
rather
bangkok
howev
evid
studi
need
confirm
origin
alarm
increas
number
confirm
case
variou
research
began
studi
estim
epidemiolog
matrix
use
describ
transmiss
infecti
agent
variou
studi
indic
number
expect
case
directli
gener
singl
infect
case
within
rang
aforement
studi
approxim
viru
incub
period
day
expect
epidem
doubl
time
could
rang
day
probabl
outbreak
locat
outsid
wuhan
estim
potenti
individuallevel
variat
transmiss
increas
variat
result
lower
possibl
outbreak
wherea
increas
transmiss
homogen
like
establish
outbreak
new
locat
research
anticip
possibl
outbreak
occur
new
locat
assum
sarslik
variat
wuhanlik
transmiss
studi
model
epidem
dynam
network
valu
obtain
via
estim
method
sequenti
markov
chain
mont
carlo
algorithm
poisson
loglikelihood
regress
algorithm
uncertainti
approxim
quantifi
bayesian
analysi
abovement
studi
simul
wuhan
epidem
dynam
network
util
determinist
susceptibleexposedinfectedrecov
seir
model
categor
popul
four
state
suscept
individu
asymptomat
individu
incub
period
e
confirm
infecti
individu
recov
individu
r
seirdc
model
enhanc
standard
seir
model
introduc
dead
auxiliari
variabl
dc
also
use
investig
geologicalstratifi
debias
approach
incorpor
seirdc
model
includ
latent
infect
ratio
l
amongst
peopl
travel
wuhan
destin
mainland
china
improv
overal
epidemiolog
estim
coronaviru
studi
infect
includ
analyz
genom
structur
examin
interact
human
receptor
establish
transmiss
network
model
analysi
major
structur
protein
includ
spike
membran
envelop
e
nucleic
capsid
n
protein
show
coronaviru
exhibit
high
degre
variat
human
sar
viru
categor
novel
type
bat
coronaviru
transmiss
coronavirus
human
part
driven
interact
spike
protein
protein
human
receptor
research
util
mont
carlo
algorithm
simul
dock
bind
process
protein
simul
result
show
bind
affin
similar
sarscov
suggest
protein
encod
genom
process
human
receptorbind
abil
thu
highli
possibl
drive
transmiss
hand
transmiss
infect
sourc
human
simul
basi
transmiss
network
model
matrix
employ
seir
model
infect
sourc
human
popul
vari
everi
updat
input
matrix
model
suggest
outbreak
occur
outbreak
termin
order
reduc
risk
contract
recommend
sever
hygien
person
practic
adopt
first
recommend
regular
wash
hand
soap
simpl
yet
effect
action
mechan
remov
pathogen
human
skin
wash
hand
second
shown
reduc
pathogen
count
roughli
wherea
second
remov
thoroughli
wash
hand
shown
reduc
respiratori
ill
gener
popul
also
highli
recommend
hand
clean
alcoholbas
hand
rub
consist
ethyl
alcohol
ethanol
isopropyl
alcohol
isopropanol
npropanol
alcohol
exhibit
rapid
broadspectrum
antimicrobi
activ
veget
bacteria
virus
fungi
optim
antimicrobi
activ
occur
alcohol
concentr
wherea
activ
significantli
lower
concentr
alcohol
use
cytoplasm
membran
viru
particl
would
damag
due
rapid
denatur
protein
make
membran
caus
viral
nucleic
acid
releas
environ
follow
capsid
destruct
viral
inactiv
also
recommend
practic
respiratori
hygien
includ
limit
cover
one
mouth
cough
sneez
coronaviru
known
spread
larger
droplet
expel
cough
sneez
also
recommend
maintain
suitabl
social
distanc
least
feet
surround
peopl
particularli
avoid
form
physic
contact
activ
might
encourag
project
transfer
small
droplet
could
potenti
carri
viru
also
recommend
wear
person
protect
equip
specif
surgic
face
mask
respir
infectioncontrol
strategi
protect
wearer
liquid
airborn
particl
surgic
face
mask
effect
block
spray
larger
droplet
prevent
reach
mouth
nose
howev
unabl
complet
block
smaller
droplet
air
might
transmit
cough
sneez
certain
medic
procedur
loos
contact
face
surfac
mask
provid
exposur
droplet
make
way
enter
mouth
nose
respir
hand
worn
correctli
block
least
small
micron
particl
make
better
option
stem
outbreak
new
coronaviru
howev
respir
need
fittest
ensur
effect
protect
prevent
govern
variou
countri
also
rais
awar
amongst
public
provid
similar
recommend
prevent
contain
justif
recommend
similar
one
describ
section
recommend
variou
countri
agenc
shown
tabl
oxygen
therapi
mechan
ventil
intraven
antibiot
oseltamivir
therapi
initi
patient
respect
antivir
therapi
appli
patient
viral
infect
alreadi
establish
host
need
control
one
prescrib
antivir
medic
patient
suffer
oseltamivir
normal
use
treat
influenza
adult
children
infant
older
week
age
experienc
clinic
symptom
day
oseltamivir
classifi
class
medicin
known
neuraminidas
inhibitor
work
stop
spread
viru
throughout
bodi
shorten
time
flu
symptom
last
neuraminidas
inhibitor
promot
releas
viru
infect
cell
facilit
viral
movement
within
respiratori
tract
virion
remain
attach
membran
infect
cell
presenc
neuraminidas
inhibitor
get
stuck
respiratori
secret
anoth
type
antivir
medic
use
patient
ganciclovir
normal
use
treat
cytomegaloviru
cmv
retin
patient
compromis
immun
system
risk
inhibit
viru
replic
ganciclovir
first
convert
activ
form
monophosph
whilst
catalyz
viruscod
cellular
enzym
known
thymidin
kinas
tk
monophosph
convert
ganciclovir
triphosph
cellular
enzym
competit
inhibit
datp
lead
format
faulti
dna
replac
mani
adenosin
base
dna
strand
prevent
dna
synthesi
remdesivir
broadspectrum
antivir
nucleotid
prodrug
shown
promis
antivir
activ
variou
coronavirus
vitro
access
activ
remdesivir
inhibit
viral
replic
initi
effici
metabol
convers
cell
tissu
activ
nucleosid
triphosph
turn
deactiv
viral
rna
polymeras
remdesivir
shown
diminish
effect
patholog
featur
acut
lung
injuri
ali
common
clinic
featur
observ
patient
previous
vivo
studi
shown
lung
injuri
score
significantli
reduc
merscovinfect
mice
treat
remdesivir
section
lung
tissu
appear
lower
concentr
debri
inflammatori
cell
deposit
thu
facilit
effici
ga
exchang
lung
compar
untreat
mice
ali
apart
lung
injuri
patient
also
develop
secondari
infect
septic
shock
widespread
infect
throughout
bodi
would
result
multipl
organ
failur
nonhuman
primat
tissu
distribut
studi
shown
remdesivir
effect
penetr
distribut
immuneprivileg
site
includ
eye
genit
tract
extent
brain
could
persist
reservoir
virus
would
allow
remdesivir
provid
wider
coverag
antivir
effect
differ
organ
bodi
thu
reduc
possibl
viru
accumul
immun
privileg
site
indic
potenti
remdesivir
antivir
drug
treat
patient
past
lopinavir
ritonavir
prescrib
patient
suffer
sarscov
merscov
reduc
clinic
symptom
combin
lopinavir
ritonavir
administ
patient
suffer
kaletra
coformul
lopinavir
ritonavir
also
test
activ
new
protein
structur
protein
dnamanufactur
enzym
made
viral
proteas
product
virus
lopinavir
prevent
cleavag
groupspecif
antigenpolymeras
gagpol
polyprotein
viru
inhibit
proteas
action
result
product
defect
immatur
noninfecti
viral
particl
coformul
kaletra
ritonavir
increas
halflif
plasma
level
lopinavir
inhibit
oxid
caus
cytochrom
drug
ribavirin
penciclovir
nitazoxanid
nafamostat
chloroquin
favipiravir
propos
test
vitro
amongst
mention
drug
ribavirin
penciclovir
favipiravir
requir
high
concentr
nucleosid
analog
reduc
viral
infect
consid
less
effect
nafamostat
nitazoxanid
capabl
prevent
membran
fusion
act
antiprotozo
agent
respect
exhibit
inhibit
activ
chloroquin
abil
interfer
glycosyl
cellular
receptor
sarscov
inhibit
viru
infect
increas
endosom
ph
requir
viru
fusion
recent
report
henc
potenti
broadspectrum
antivir
drug
therefor
nafamostat
nitazoxanid
chloroquin
high
potenti
recommend
evalu
vivo
patient
suffer
anoth
effect
antivir
strategi
disrupt
protein
kinas
regul
virus
passag
cell
via
endocytosi
amongst
inhibitor
approv
medic
use
studi
oncolog
drug
sunitinib
erlotinib
shown
effect
viral
infect
inhibit
howev
side
effect
coexist
usag
could
support
safe
therapi
sick
infect
patient
altern
highaffin
drug
baricitinib
found
bind
anoth
regul
endocytosi
cyclin
gassoci
kinas
henc
baricitinib
appear
potenti
kinaseinhibit
drug
drug
target
viral
proteas
highli
conserv
key
enzym
coronaviru
replic
commonli
capabl
prevent
prolifer
viru
prulifloxacin
bictegravir
nelfinavir
tegobuvi
proteasetarget
drug
interrupt
dimer
format
proteas
valrubicin
icatib
bepotastin
epirubicin
epoprostenol
vapreotid
aprepit
caspofungin
examin
via
virtual
dock
appear
exhibit
high
hydrogen
bond
bind
main
proteas
mpro
success
interf
function
mpro
basi
result
antivir
drug
propos
could
serv
potenti
candid
proteasetarget
treatment
develop
treat
current
studi
limit
number
detail
investig
carri
specif
wang
et
al
examin
effect
seri
antivir
drug
includ
ribavirin
penciclovir
nitazoxanid
nafamostat
favipiravir
chloroquin
remdesivir
vitro
promis
result
shown
valu
remdesivir
vero
cell
suggest
work
concentr
like
achiev
nonhuman
primat
model
remdesivir
found
inhibit
viru
infect
effici
human
cell
line
human
liver
cancer
cell
sensit
contrari
antivir
drug
oseltamivir
kaletra
test
merscov
rather
antibiot
prescrib
patient
low
immun
function
name
elderli
medic
fragil
patient
administr
antibiot
prevent
bacteri
coinfect
whilst
strengthen
immun
support
lead
better
chanc
recoveri
antibiot
treatment
demonstr
posit
therapeut
outcom
variou
clinic
studi
specif
cephalosporin
carbapenem
quinolon
antibiot
given
patient
either
singl
multiantibiot
treatment
parallel
antivir
agent
epidemiolog
studi
report
combin
treatment
seen
success
treat
patient
reportedli
recov
discharg
hospit
cephalosporin
bactericid
betalactam
antibiot
disrupt
bacteri
cell
synthesi
inhibit
enzym
action
cell
wall
suscept
bacteria
cephalosporin
bind
penicillinbind
protein
pbp
bacteri
enzym
respons
synthes
peptidoglycan
thu
affect
structur
integr
bacteri
cell
wall
inhibit
cell
wall
format
integr
part
bacteri
structur
cell
surviv
result
bacteria
suscept
surround
attack
eventu
lead
cell
death
similar
cephalosporin
carbapenem
disrupt
cell
wall
format
bacteria
inhibit
activ
site
pbp
addit
carbapenem
obstruct
peptidas
reaction
peptid
crosslink
bind
peptidas
domain
activ
pbp
inhibit
whilst
autolysi
process
develop
cell
wall
format
peptidoglycan
layer
weaken
follow
bacteria
burst
due
osmot
pressur
quinolon
exhibit
antimicrobi
effect
convert
enzym
essenti
bacteri
dna
replic
transcript
name
gyras
topoisomeras
iv
toxic
enzym
would
fragment
bacteri
chromosom
quinolon
bind
interfac
interact
protein
whilst
intercal
dna
cleav
scissil
bond
drugstabil
topoisomeras
cleavag
complex
collid
transcript
complex
replic
complex
convert
perman
chromosom
break
excess
dna
breakag
disrupt
cell
function
result
bacteri
death
examin
function
coronaviru
bind
propos
protein
hypothes
exert
neutral
potenti
coronaviru
especi
fusion
protein
construct
extracellular
domain
human
receptor
link
fc
domain
human
immunoglobulin
test
sarscov
half
maxim
inhibitori
concentr
test
vitro
neutral
sarscov
crossreact
high
bind
affin
fusion
protein
receptorbind
domain
rbd
sarscov
suggest
potenti
treatment
strategi
coronaviru
vaccin
convert
viral
spike
protein
sequenc
messeng
rna
mrna
develop
vitro
transcrib
mrna
engin
resembl
fulli
process
matur
mrna
molecul
could
degrad
quickli
extracellular
rnase
cellular
translat
machineri
take
place
mrna
enter
cytosol
fulli
function
protein
produc
postproteintransl
modif
vaccin
anticip
initi
immun
cell
lymph
process
code
mrna
turn
produc
protein
manner
immun
cell
recogn
begin
mount
relev
respons
actual
viral
infect
dna
vaccin
encod
first
amino
acid
merscov
spike
protein
shown
increas
secret
interferon
gamma
cytokin
antigenspecif
often
known
helper
cell
often
known
cytotox
killer
cell
cell
induc
protect
merscov
progress
develop
merscov
vaccin
dna
vaccin
reli
spike
protein
also
close
studi
propos
vaccin
target
viral
dna
sequenc
expect
prepar
immun
system
launch
strong
respons
pathogen
known
associ
overt
inflammatori
respons
use
mesenchym
stromal
cell
obtain
allogen
donor
cellular
therapi
facilit
regener
damag
cell
thu
effect
reduc
nonproduct
inflamm
patient
studi
shown
autolog
hematopoiet
stemcel
transplant
could
result
shortterm
expans
isol
antivirusdirect
cell
cytomegaloviru
infect
treatment
henc
expans
cell
believ
potenti
adjunct
treatment
patient
diagnos
depict
common
epitop
essenti
design
univers
potent
subunit
vaccin
epitop
commonli
recogn
domin
human
leukocyt
isotyp
hladr
major
histocompat
complex
class
ii
cell
surfac
glycoprotein
allel
investig
eight
immunodomin
hladr
epitop
distribut
across
spike
envelop
membran
protein
exhibit
high
affin
suggest
potenti
effect
antivir
cell
antibodi
respons
similarli
screen
sarscovderiv
b
cell
epitop
epitop
sequenc
structur
protein
compris
mutat
ident
match
exist
protein
sequenc
therefor
epitop
great
potenti
elicit
effect
crossreact
respons
accord
exist
case
studi
numer
case
patient
recov
februari
total
patient
variou
countri
receiv
relev
medic
treatment
discharg
hospit
promis
start
number
still
increas
trend
chines
femal
patient
combin
treatment
oseltamivir
lopinavir
ritonavir
test
neg
viral
infect
hour
consecut
discharg
februari
cabl
news
network
cnn
report
first
us
patient
washington
man
treat
discharg
hospit
remain
isol
home
whilst
close
monitor
snohomish
health
district
februari
man
wuhan
china
discharg
hospit
singapor
prior
discharg
test
neg
continu
day
day
girl
malaysia
discharg
hospit
langkawi
februari
two
patient
suburban
chicago
discharg
hospit
remain
selfquarantin
observ
februari
man
wuhan
discharg
permai
hospit
johor
bahru
malaysia
treat
kaletra
day
china
patient
wuhan
jin
yintan
hospit
discharg
januari
similarli
epidemiolog
studi
patient
wuhan
report
patient
recov
discharg
januari
date
februari
total
patient
report
recoveri
wuhan
alon
confirm
case
hospit
discharg
rate
vari
differ
hospit
wuhan
wherea
averag
recoveri
rate
record
across
china
anoth
report
clinic
characterist
pregnant
patient
zhongnan
hospit
wuhan
univers
studi
order
investig
potenti
intrauterin
vertic
transmiss
found
clinic
characterist
pregnant
patient
similar
nonpregn
adult
patient
amongst
nine
pregnant
patient
provid
antibiot
treatment
nasal
cannula
oxygen
support
whilst
given
antivir
drug
februari
nine
live
birth
record
evid
vertic
transmiss
late
pregnanc
patient
current
medic
strategi
administ
patient
diagnos
mainli
includ
use
antivir
drug
antibiot
agent
sever
case
oxygen
therapi
renal
replac
therapi
well
depend
sever
symptom
either
singl
combin
treatment
given
patient
antivir
treatment
primarili
use
oseltamivir
ganciclovir
kaletra
combin
lopinavir
ritonavir
prescrib
treat
ard
minim
potenti
septic
shock
parallel
patient
also
given
either
singl
combin
treatment
antibiot
agent
name
cephalosporin
quinolon
carbapenem
prevent
secondari
infect
strengthen
immun
system
sever
case
oxygen
therapi
renal
replac
therapi
provid
support
treatment
maintain
function
vital
organ
throughout
treatment
recoveri
period
oxygen
therapi
includ
nasal
cannula
highflow
nasal
cannula
invas
mechan
ventil
extracorpor
membran
oxygen
ecmo
given
patient
suffer
ard
oxygen
defici
due
impair
lung
function
ensur
adequ
ventil
healthi
concentr
oxygen
throughout
bodi
oxygen
therapi
eas
symptom
hypoxemia
prevent
organ
damag
renal
replac
therapi
replac
nonendocrin
kidney
function
patient
renal
failur
continu
renal
replac
therapi
crrt
prescrib
patient
acut
renal
failur
reduc
solut
imbal
toxic
overload
could
result
multiorgan
failur
basi
current
studi
would
appear
combin
antivir
antibiot
support
treatment
potenti
provid
higher
success
rate
treat
patient
particularli
moder
sever
ard
epidemiolog
studi
patient
wuhan
patient
prescrib
antivir
oseltamivir
addit
patient
receiv
antibiot
treatment
patient
oxygen
therapi
patient
given
crrt
discharg
rate
hospit
high
similar
combin
treatment
report
promis
result
collect
studi
involv
patient
hospit
across
provinc
mainland
china
anoth
epidemiolog
studi
involv
patient
wuhan
combin
oseltamivir
ganciclovir
kaletra
prescrib
patient
total
patient
provid
singl
antibiot
treatment
whilst
patient
receiv
multiantibiot
treatment
patient
studi
oxygen
therapi
crrt
respect
eventu
patient
discharg
hospit
addit
sever
studi
report
effect
use
kaletra
suppress
activ
medic
team
china
singapor
malaysia
thailand
observ
promis
effect
kaletra
combin
medic
intervent
treat
patient
lead
mani
discharg
hospit
said
present
avail
vaccin
medic
treatment
could
prevent
infect
addit
continu
ongo
effort
need
theoret
clinic
fulli
understand
effect
treatment
prevent
recent
epidem
outbreak
ongo
crisi
caus
global
uncertainti
unpreced
scale
zoonot
pathogen
identifi
envelop
positivesens
singlestrand
rna
betacoronaviru
similar
bat
coronaviru
term
batcov
believ
origin
infect
bat
transmiss
anim
human
well
human
human
day
incub
period
februari
stagger
confirm
case
diseas
associ
infect
fatal
report
worldwid
although
current
mortal
rate
rel
low
approxim
compar
sar
mer
highli
contagi
infect
patient
sar
mer
combin
shorter
period
time
signific
amount
collect
work
done
china
global
first
day
outbreak
particularli
understand
novel
coronaviru
well
devis
prevent
treatment
strategi
strict
contain
measur
effect
implement
throughout
china
particularli
infect
area
prevent
uncontrol
spread
statist
studi
shown
reproduct
number
high
declin
trend
indic
lower
spread
rate
contain
strict
isol
measur
promis
medic
intervent
administ
patient
total
patient
discharg
hospit
variou
countri
februari
said
avail
vaccin
littl
still
known
posteffect
clearli
continu
effort
across
world
need
fulli
understand
coronaviru
famili
order
prevent
futur
outbreak
